Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to specific share transactions:
- Transaction Price: $47.488 per American Depositary Share (ADS).
- Transaction Date: April 18, 2013 (following dividend reinvestment on April 11, 2013).
- Participants: Mrs. D P Connelly and Mr. W C Louv.
Material Changes
The filing details increases in ADS holdings for two individuals under the Deferred Annual Bonus Plan:
- Mrs. D P Connelly: Acquired 30.612 ADSs (personal contribution) and 31.302 ADSs (company matching contribution).
- Mr. W C Louv: Acquired 32.478 ADSs (personal contribution) and 33.192 ADSs (company matching contribution).
These transactions relate to deferred bonuses from 2010 and 2011 on a post-tax basis.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of insider transactions compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the vesting schedule for the 2010 and 2011 deferred bonus awards mentioned.
- Confirm the total number of ADSs held by Mrs. Connelly and Mr. Louv post-transaction.
- Review the terms of the GlaxoSmithKline 2009 Deferred Annual Bonus Plan regarding the three-year measurement period.